San Diego, Calif. – DIA’s 45th Annual Meeting – June 23, 2009– Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today pointed to a growing list of customers adopting its Empirica™ Trace safety solution over the past year for comprehensive adverse event management. Among others, customers such as Thallion Pharmaceuticals, Panacea Pharma Projects Limited, Bavarian Nordic A/S, Alapis S.A, and the International Institute for the Safety of Medicines Ltd. (ii4sm) are turning to Empirica Trace to efficiently capture and manage spontaneous report data across the full product life cycle, from clinical development through post-marketing.
“We believe that the marked increase in customer pick-up is a clear indicator that our Empirica Trace product is meeting a need across organizations of all sizes and therapeutic areas for a comprehensive safety solution,” said Chan Russell, president, Phase Forward’s Lincoln Safety Group. “These customers tell us that Empirica Trace provides a fundamental building block for efficiently capturing and managing adverse event data.”
The Empirica Suite of Products
The Empirica Suite of products is Phase Forward’s complete solution set for pharmacovigilance and risk management. In addition to the Empirica Trace product, the suite includes Empirica Study (see related release: Phase Forward Introduces Empirica™ Study, Major New Release of Clinical Trials Signal Detection Solution), an award-winning product that provides a dynamic visual data environment for reviewing safety data and detecting signals in trial data, and the Empirica Gateway E2B submission product which offers full support for E2B submission of case reports to regulators, affiliates and partners and receipt of data via E2B standard files. The suite also includes Empirica Signal, a state-of-the-art data mining and signal management product. It provides detection and quantification of safety signals through the use of advanced data mining techniques that can be applied to any spontaneous reporting database.
The Empirica Suite of products, together with the InForm™ Global Trial Management (GTM) eClinical product, the Clarix™ interactive response technology (IRT) for randomization and trial supply management and the recently acquired Waban Software platform for the management of all product safety data, analysis and reports, offers an integrated clinical research system (ICRS) for today’s life science professionals.
Phase Forward will be showcasing its products including Empirica Trace at DIA’s 45th Annual Meeting in San Diego at booth #729.
About Phase Forward
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 290 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.